Recipe - Compounding Worksheet
Unauthorized distribution, copying or disclosure prohibited.
These recipes are intended for use by the pharmacy manufacturing departments only.
Cidofovir Topical Cream (LOW STRENGTH)   1%
Lot No Expiry(mm/yyyy) Ingredients Master Formula
    cidofovir  75 mg/mL  INJ   
    Eucerin    CRM   
Recipe Total Quantity:
Final Quantity Desired: g

Directions: HAZARDOUS - Potential
Refer to the AHS Hazardous Medication Handling Guide for more information.

Prepare in a biological safety cabinet using aseptic technique whenever possible.

1. Weigh the cream/ vehicle base.
2. Backload cream base into a disposable 60 mL syringe.
3. Place the syringe into a hood.
4. Withdraw the desired amount of cidofovir into another disposable 60 mL syringe.
5. Attach a luer lock-to–leur lock connector to the syringe.
6. Connect the syringe containing cream base to the connector.
7. Inject the contents of the syringes back and forth between the two syringes until the cream base is thoroughly mixed with the cidofovir solution and the mixture is smooth and consistent in texture.
8. Detach the connector and transfer the mixture to a clean jar.

Notes Cidofovir 75 mg/mL injection is available through Health Canada's Special Access Program.

The syringe method of preparation is ideal when the amount of cream or gel compounded is usually less than 40 g.

NOTE: Velvachol, Pentravan (Gallipot), Dermovan or a propylene glycol-based jelly can be used instead of Eucerin.

Packaging:  Ointment Jar

Auxiliary Labels: For External Use Only
  Hazardous medication - use safe handling precautions
  Note Strength
  Protect From Light
  Store at Room Temperature

Storage/Expiry:Room Temperature: 30 days

Last Date Revised: 17-May-18

References: AHS Hazardous Medication Handling information available on Insite:

National Institute of Health Clinical Center Pharmacy Department Dr. Bethseda MD 20892 301-496-4363. (Received December 27, 2012 from Jae Kim compounding pharmacist).

Toro JR, et al. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136(8): 983-985.

Velasco AA, et al. Topical cidofovir for the treatment of resistant viral infections: a case report. EJHP Science 2009; 15(4): 83-85.

McElhiney LF. Topical cidofovir: for treatment of resistant viral infections. International Journal of Pharmaceutical Compounding 2006 (Sept/Oct); 10(5): 324-328.

Completed Compound Check
Lot NoDate Prepared Expiry DateTechnicianPharmacist

This content is provided for general information purposes only. It is not intended to replace consultations with a health care professional or to provide medical advice, diagnosis or treatment. Always seek the advice of a physician or other qualified health care provider with any medical or health questions. Alberta Health Services accepts no responsibility for any modification or redistribution of this document and is not liable for any actions taken by individuals based on the information provided, or for any inaccuracies, errors, or omissions in the information in this document. These recipes are to be used as a reference and are not intended to be master formulation records. Not all recipes may be compliant with NAPRA or other standards.